Table 1.
Demographic and clinical characteristics of CD patients with percutaneously undrainable abscesses by the treatment group.
| Characteristics | EEN group (n = 54) | Non-EEN group (n = 29) | P |
|---|---|---|---|
| Gender, n (male/female) | 32/22 | 15/14 | 0.509 |
| Age at onset of abscess (y), median (range) | 32.8 (17–51) | 37.1 (17–60) | 0.094 |
| Disease duration (y), median (range) | 4.3 (0.16–30) | 5.5 (0.1–20) | 0.274 |
| Previous abdominal surgery, n (%) | 11 (20.4) | 8 (27.6) | 0.456 |
| Montreal classification of age, n (%) | 0.526 | ||
| A1 (<16 years) | 0 (0) | 0 (0) | |
| A2 (17–40 years) | 39 (72.2) | 19 (65.5) | |
| A3 (>40 years) | 15 (27.8) | 10 (34.5) | |
| Montreal classification of disease location, n (%) | 1.000 | ||
| L1 (ileal) | 18 (33.3) | 10 (34.5) | |
| L2 (colonic) | 2 (3.7) | 1 (3.4) | |
| L3 (ileocolonic) | 34 (63.0) | 18 (62.1) | |
| Abscess location, n (%) | 0.574 | ||
| Right lower quadrant | 24 (44.4) | 13 (44.8) | |
| Pelvis | 18 (33.3) | 7 (24.1) | |
| Others | 12 (22.2) | 9 (31.0) | |
| Multiple abscesses, n (%) | 8 (14.8) | 7 (24.1) | 0.293 |
| Abscess diameter > 3 cm, n (%) | 11 (11.1) | 11 (24.1) | 0.084 |
| Fistula, n (%) | 31 (57.4) | 11 (37.9) | 0.091 |
| Perianal lesion, n (%) | 7 (13.0) | 7 (24.1) | 0.227 |
| Steroids at diagnosis, n (%) | 18 (33.3) | 14 (48.3) | 0.182 |
| AZA/6-MP at diagnosis, n (%) | 20 (37.0) | 14 (48.3) | 0.321 |
| Infliximab at diagnosis, n (%) | 7 (13.0) | 3 (10.3) | 1.000 |
| Laboratory indices | |||
| White blood cell (×109/L), mean, (range) | 8.8 (3.6–15) | 7.1 (2.7–11.6) | 0.012 |
| Hemoglobin (g/L), mean (range) | 11.8 (6.1–15.8) | 10.9 (6.6–14.1) | 0.366 |
| ESR (mm/h), mean (range) | 36.7 (2–92) | 33.3 (2–96) | 0.574 |
| C-reactive protein (mg/L), mean (range) | 56.4 (3.9–202.4) | 32.6 (0.4–159) | 0.029 |
| Albumin (g/L), mean (range) | 32.5 (19.5–41.1) | 30.8 (17–40.3) | 0.216 |
ESR: erythrocyte sedimentation rate; EEN: exclusive enteral nutrition; AZA: azathioprine; 6-MP: mercaptopurine.